Magnetic Resonance Elastography Predicts Advanced Fibrosis in Patients with Nonalcoholic Fatty Liver Disease: a Prospective Study

Overview

Journal Hepatology

Specialty Gastroenterology

Date 2014 Aug 9

PMID 25103310

Citations 215

Authors

Rohit Loomba

Tanya Wolfson

Brandon Ang

Jonathan Hooker

Cynthia Behling

Michael Peterson

Mark Valasek

Grace Lin

David Brenner

Anthony Gamst

Richard Ehman

Claude Sirlin

Affiliations

Soon will be listed here.

Abstract

Unlabelled: Retrospective studies have shown that two-dimensional magnetic resonance elastography (2D-MRE), a novel MR method for assessment of liver stiffness, correlates with advanced fibrosis in patients with nonalcoholic fatty liver disease (NAFLD). Prospective data on diagnostic accuracy of 2D-MRE in the detection of advanced fibrosis in NAFLD are needed. The aim of this study is to prospectively assess the diagnostic accuracy of 2D-MRE, a noninvasive imaging biomarker, in predicting advanced fibrosis (stage 3 or 4) in well-characterized patients with biopsy-proven NAFLD. This is a cross-sectional analysis of a prospective study including 117 consecutive patients (56% women) with biopsy-proven NAFLD who underwent a standardized research visit: history, exam, liver biopsy assessment (using the nonalcoholic steatohepatitis Clinical Research Network histological scoring system), and 2D-MRE from 2011 to 2013. The radiologist and pathologist were blinded to clinical and pathology/imaging data, respectively. Receiver operating characteristics (ROCs) were examined to assess the diagnostic test performance of 2D-MRE in predicting advanced fibrosis. The mean (± standard deviation) of age and body mass index was 50.1 (± 13.4) years and 32.4 (± 5.0) kg/m(2), respectively. The median time interval between biopsy and 2D-MRE was 45 days (interquartile range: 50 days). The number of patients with fibrosis stages 0, 1, 2, 3, and 4 was 43, 39, 13, 12, and 10, respectively. The area under the ROC curve for 2D-MRE discriminating advanced fibrosis (stage 3-4) from stage 0-2 fibrosis was 0.924 (P < 0.0001). A threshold of >3.63 kPa had a sensitivity of 0.86 (95% confidence interval [CI]: 0.65-0.97), specificity of 0.91 (95% CI: 0.83-0.96), positive predictive value of 0.68 (95% CI: 0.48-0.84), and negative predictive value of 0.97 (95% CI: 0.91-0.99).

Conclusions: MRE is accurate in predicting advanced fibrosis and may be utilized for noninvasive diagnosis of advanced fibrosis in patients with NAFLD.

Citing Articles

Accuracy of Velacur in Assessing MASLD and MASH Patients Using Biopsy as the Gold Standard.

Sheikh M, Hasan N, Almozuaghi M, Akhtar N, Grewal Y, Schneider C Diagnostics (Basel). 2025; 15(5).

PMID: 40075862 PMC: 11898527. DOI: 10.3390/diagnostics15050615.

Alterations of hepatic lipid content following COVID-19 in persons with type 2 diabetes.

Kupriyanova Y, Yurchenko I, Bobrov P, Bartels F, Wierichs S, Jonuscheit M BMJ Open Diabetes Res Care. 2025; 13(1).

PMID: 39965871 PMC: 11836859. DOI: 10.1136/bmjdrc-2024-004727.

Impact of shear wave elastography and attenuation imaging for predicting life-threatening event in patients with metabolic dysfunction-associated steatotic liver disease.

Fujiwara Y, Kuroda H, Abe T, Nagasawa T, Nakaya I, Ito A Sci Rep. 2025; 15(1):4547.

PMID: 39915518 PMC: 11802924. DOI: 10.1038/s41598-025-87974-w.

Impact of liver graft steatosis on long-term post-transplant hepatic steatosis and fibrosis via magnetic resonance quantification.

Mak L, Fung J, Lo G, Lo C, Wu T, Chung M Front Med (Lausanne). 2025; 11:1502055.

PMID: 39895824 PMC: 11782125. DOI: 10.3389/fmed.2024.1502055.

Head-to-Head Comparison Between Phosphatidylethanol Versus Indirect Alcohol Biomarkers for Diagnosis of MetALD Versus MASLD: A Prospective Study.

Tavaglione F, Amangurbanova M, Yang A, Tincopa M, Ajmera V, Richards L Aliment Pharmacol Ther. 2025; 61(6):1043-1054.

PMID: 39825487 PMC: 11870800. DOI: 10.1111/apt.18506.

References

Noureddin M, Loomba R . Nonalcoholic fatty liver disease: Indications for liver biopsy and noninvasive biomarkers. Clin Liver Dis (Hoboken). 2019; 1(4):104-107. PMC: 6499277. DOI: 10.1002/cld.65. View

Kim D, Kim W, Talwalkar J, Kim H, Ehman R . Advanced fibrosis in nonalcoholic fatty liver disease: noninvasive assessment with MR elastography. Radiology. 2013; 268(2):411-9. PMC: 3721049. DOI: 10.1148/radiol.13121193. View

Yin M, Talwalkar J, Glaser K, Manduca A, Grimm R, Rossman P . Assessment of hepatic fibrosis with magnetic resonance elastography. Clin Gastroenterol Hepatol. 2007; 5(10):1207-1213.e2. PMC: 2276978. DOI: 10.1016/j.cgh.2007.06.012. View

Liu C, McKenzie C, Yu H, Brittain J, Reeder S . Fat quantification with IDEAL gradient echo imaging: correction of bias from T(1) and noise. Magn Reson Med. 2007; 58(2):354-64. DOI: 10.1002/mrm.21301. View

Permutt Z, Le T, Peterson M, Seki E, Brenner D, Sirlin C . Correlation between liver histology and novel magnetic resonance imaging in adult patients with non-alcoholic fatty liver disease - MRI accurately quantifies hepatic steatosis in NAFLD. Aliment Pharmacol Ther. 2012; 36(1):22-9. PMC: 3437221. DOI: 10.1111/j.1365-2036.2012.05121.x. View

Reeder S, Hu H, Sirlin C . Proton density fat-fraction: a standardized MR-based biomarker of tissue fat concentration. J Magn Reson Imaging. 2012; 36(5):1011-4. PMC: 4779595. DOI: 10.1002/jmri.23741. View

Adams L, Sanderson S, Lindor K, Angulo P . The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies. J Hepatol. 2005; 42(1):132-8. DOI: 10.1016/j.jhep.2004.09.012. View

Myers R, Pomier-Layrargues G, Kirsch R, Pollett A, Duarte-Rojo A, Wong D . Feasibility and diagnostic performance of the FibroScan XL probe for liver stiffness measurement in overweight and obese patients. Hepatology. 2011; 55(1):199-208. DOI: 10.1002/hep.24624. View

Guha I, Parkes J, Roderick P, Chattopadhyay D, Cross R, Harris S . Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: Validating the European Liver Fibrosis Panel and exploring simple markers. Hepatology. 2007; 47(2):455-60. DOI: 10.1002/hep.21984. View

10.

Wong V, Vergniol J, Wong G, Foucher J, Chan A, Chermak F . Liver stiffness measurement using XL probe in patients with nonalcoholic fatty liver disease. Am J Gastroenterol. 2012; 107(12):1862-71. DOI: 10.1038/ajg.2012.331. View

11.

Bonekamp S, Tang A, Mashhood A, Wolfson T, Changchien C, Middleton M . Spatial distribution of MRI-Determined hepatic proton density fat fraction in adults with nonalcoholic fatty liver disease. J Magn Reson Imaging. 2014; 39(6):1525-32. PMC: 4083476. DOI: 10.1002/jmri.24321. View

12.

Loomba R, Abraham M, Unalp A, Wilson L, Lavine J, Doo E . Association between diabetes, family history of diabetes, and risk of nonalcoholic steatohepatitis and fibrosis. Hepatology. 2012; 56(3):943-51. PMC: 3407289. DOI: 10.1002/hep.25772. View

13.

Venkatesh S, Yin M, Ehman R . Magnetic resonance elastography of liver: technique, analysis, and clinical applications. J Magn Reson Imaging. 2013; 37(3):544-55. PMC: 3579218. DOI: 10.1002/jmri.23731. View

14.

Welsh J, Karpen S, Vos M . Increasing prevalence of nonalcoholic fatty liver disease among United States adolescents, 1988-1994 to 2007-2010. J Pediatr. 2012; 162(3):496-500.e1. PMC: 3649872. DOI: 10.1016/j.jpeds.2012.08.043. View

15.

Zarrinpar A, Loomba R . Review article: the emerging interplay among the gastrointestinal tract, bile acids and incretins in the pathogenesis of diabetes and non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2012; 36(10):909-21. PMC: 3535499. DOI: 10.1111/apt.12084. View

16.

Williams C, Stengel J, Asike M, Torres D, Shaw J, Contreras M . Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology. 2010; 140(1):124-31. DOI: 10.1053/j.gastro.2010.09.038. View

17.

Xanthakos S, Podberesky D, Serai S, Miles L, King E, Balistreri W . Use of magnetic resonance elastography to assess hepatic fibrosis in children with chronic liver disease. J Pediatr. 2013; 164(1):186-8. PMC: 3872246. DOI: 10.1016/j.jpeds.2013.07.050. View

18.

Angulo P, Keach J, Batts K, Lindor K . Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology. 1999; 30(6):1356-62. DOI: 10.1002/hep.510300604. View

19.

Kleiner D, Brunt E, Van Natta M, Behling C, Contos M, Cummings O . Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005; 41(6):1313-21. DOI: 10.1002/hep.20701. View

20.

Palmeri M, Wang M, Rouze N, Abdelmalek M, Guy C, Moser B . Noninvasive evaluation of hepatic fibrosis using acoustic radiation force-based shear stiffness in patients with nonalcoholic fatty liver disease. J Hepatol. 2011; 55(3):666-672. PMC: 3092839. DOI: 10.1016/j.jhep.2010.12.019. View